NAS:INCY (USA) Also trade in: Austria Germany Mexico UK

Incyte Corp

$ 80.23 0.35 (0.44%)
Volume: 901,880 Avg Vol (1m): 1,190,930
Market Cap $: 17.29 Bil Enterprise Value $: 15.73 Bil
P/E (TTM): 68.91 P/B: 8.39
Earnings Power Value 9.64
Net Current Asset Value 5.69
Tangible Book 7.92
Projected FCF 12.52
Median P/S Value 173.55
Graham Number 14.44
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8.8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 89.59
Cash-To-Debt range over the past 10 years
Min: 0.35, Med: 1.56, Max: 10000
Current: 89.59
0.35
10000
Equity-to-Asset 0.76
Equity-to-Asset range over the past 10 years
Min: -1.83, Med: 0.25, Max: 0.92
Current: 0.76
-1.83
0.92
Debt-to-Equity 0.01
Debt-to-Equity range over the past 10 years
Min: -17.62, Med: 0.01, Max: 97.27
Current: 0.01
-17.62
97.27
Debt-to-EBITDA 0.06
Debt-to-EBITDA range over the past 10 years
Min: -14.97, Med: 1.7, Max: 173.16
Current: 0.06
-14.97
173.16
Interest Coverage 198.65
Interest Coverage range over the past 10 years
Min: 0.02, Med: 1.11, Max: 198.65
Current: 198.65
0.02
198.65
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 16.18
DISTRESS
GREY
SAFE
Beneish M-Score -2.65
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 56.87%
WACC 7.99%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 14.85
Operating Margin range over the past 10 years
Min: -1508.56, Med: -0.28, Max: 14.85
Current: 14.85
-1508.56
14.85
Net Margin % 12.66
Net Margin range over the past 10 years
Min: -2286.78, Med: -16.84, Max: 12.66
Current: 12.66
-2286.78
12.66
ROE % 13.78
ROE range over the past 10 years
Min: -30.55, Med: 10.38, Max: 35.29
Current: 13.78
-30.55
35.29
ROA % 10.02
ROA range over the past 10 years
Min: -45.58, Med: -10.12, Max: 10.02
Current: 10.02
-45.58
10.02
ROC (Joel Greenblatt) % 85.39
ROC (Joel Greenblatt) range over the past 10 years
Min: -2540.65, Med: 13.38, Max: 115.22
Current: 85.39
-2540.65
115.22
3-Year Total Revenue Growth Rate 35.70
3-Year Revenue Growth Rate range over the past 10 years
Min: -61.4, Med: 29.1, Max: 523.4
Current: 29.4
-61.4
523.4
3-Year Total EBITDA Growth Rate 20.60
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -91.7, Max: 226.7
Current: 15.1
0
226.7
3-Year EPS w/o NRI Growth Rate 157.10
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -29.1, Max: 157.1
Current: 157.1
0
157.1

» INCY's 30-Y Financials

Financials (Next Earnings Date: 2019-07-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:INCY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare XKRX:207940 XBRU:UCB NAS:BMRN XKRX:068270 OCSE:NZYM B HKSE:01177 OCSE:GEN NAS:SRPT NAS:SGEN HKSE:02269 NAS:ARRY NAS:SAGE NAS:IONS SZSE:000661 NAS:JAZZ NAS:TECH NAS:ALNY NAS:NBIX HKSE:06160 NAS:LOXO
Traded in other countries ICY.Germany 0J9P.UK
Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including IDO inhibitor epacadostat and next-generation JAK inhibitor itacitinib.

Ratios

Current vs industry vs history
PE Ratio (TTM) 68.91
PE Ratio range over the past 10 years
Min: 63.21, Med: 217.07, Max: 11323
Current: 68.91
63.21
11323
Forward PE Ratio 37.74
N/A
PE Ratio without NRI 68.91
PE without NRI range over the past 10 years
Min: 63.21, Med: 217.07, Max: 11323
Current: 68.91
63.21
11323
Price-to-Owner-Earnings 94.32
Price-to-Owner-Earnings range over the past 10 years
Min: 10.73, Med: 99.13, Max: 553.9
Current: 94.32
10.73
553.9
PB Ratio 8.39
PB Ratio range over the past 10 years
Min: 6.5, Med: 27.18, Max: 391.93
Current: 8.39
6.5
391.93
PS Ratio 8.72
PS Ratio range over the past 10 years
Min: 6.7, Med: 18.77, Max: 239.71
Current: 8.72
6.7
239.71
Price-to-Free-Cash-Flow 44.53
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.24, Med: 126.97, Max: 13461.43
Current: 44.53
7.24
13461.43
Price-to-Operating-Cash-Flow 37.03
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 7.19, Med: 92.39, Max: 974.08
Current: 37.03
7.19
974.08
EV-to-EBIT 60.19
EV-to-EBIT range over the past 10 years
Min: -8534.9, Med: -10.7, Max: 1569.2
Current: 60.19
-8534.9
1569.2
EV-to-EBITDA 49.66
EV-to-EBITDA range over the past 10 years
Min: -8534.9, Med: -12.65, Max: 1569.2
Current: 49.66
-8534.9
1569.2
EV-to-Revenue 7.86
EV-to-Revenue range over the past 10 years
Min: 6, Med: 19.15, Max: 273.2
Current: 7.86
6
273.2
Current Ratio 5.22
Current Ratio range over the past 10 years
Min: 1.51, Med: 4.34, Max: 21.14
Current: 5.22
1.51
21.14
Quick Ratio 5.21
Quick Ratio range over the past 10 years
Min: 1.51, Med: 4.32, Max: 21.14
Current: 5.21
1.51
21.14
Days Inventory 22.65
Days Inventory range over the past 10 years
Min: 14.47, Med: 26.08, Max: 323.15
Current: 22.65
14.47
323.15
Days Sales Outstanding 44.60
Days Sales Outstanding range over the past 10 years
Min: 12.25, Med: 52.27, Max: 6447.52
Current: 44.6
12.25
6447.52
Days Payable 260.52
Days Payable range over the past 10 years
Min: 260.52, Med: 474.22, Max: 32457.1
Current: 260.52
260.52
32457.1

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.50
3-Year Share Buyback Rate range over the past 10 years
Min: -17.8, Med: -7.6, Max: -0.6
Current: -4.5
-17.8
-0.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 10.18
Price-to-Tangible-Book range over the past 10 years
Min: 0.91, Med: 6.76, Max: 340.56
Current: 10.18
0.91
340.56
Price-to-Projected-FCF 6.44
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 5.95, Med: 16.69, Max: 138.66
Current: 6.44
5.95
138.66
Price-to-Median-PS-Value 0.46
Price-to-Median-PS-Value range over the past 10 years
Min: 0.12, Med: 0.89, Max: 11.57
Current: 0.46
0.12
11.57
Price-to-Graham-Number 5.58
Price-to-Graham-Number range over the past 10 years
Min: 4.27, Med: 7.03, Max: 241
Current: 5.58
4.27
241
Earnings Yield (Joel Greenblatt) % 1.69
Earnings Yield (Greenblatt) range over the past 10 years
Min: -37.7, Med: -0.6, Max: 1.8
Current: 1.69
-37.7
1.8

More Statistics

Revenue (TTM) (Mil) $ 1,997.46
EPS (TTM) $ 1.17
Beta 0.98
Volatility % 34.4
52-Week Range $ 57 - 89.3
Shares Outstanding (Mil) 213.27

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N